Purpose of the test
Anti-soluble liver antigen (anti-SLA) is one of a number of autoantibodies associated with autoimmune hepatitis (AIH). However, it is not unique to AIH and has been described in 10% of patients with chronic hepatitis C virus infection (1). It has been suggested that anti-SLA be used to categorise a subtype of AIH, namely AIH type 3 (type 1 being associated with smooth muscle antibody and/or anti-nuclear antibody; type 2 with anti-liver kidney and/or anti-liver cytosol-1). This suggestion has not been universally accepted. Anti-SLA is found in patients with type 1 and type 2 AIH (2).
Serum 2.0 ml.
Storage and Transport
Samples may be stored at 4°C prior to despatch. The use of first class letter post without the need for coolant is sufficient.
Assay is performed weekly but samples with clinical urgency can be processed on the day of receipt. If this is required, a telephone call to this department prior to dispatch is essential.
Time Limit for Extra Tests
Factors affecting results or interpretation
All tests are compromised by prolonged transit times. For this reason, date of bleed and date of postage must be provided with each request.
Refer to Autoimmune Liver Blot Screen test information sheet
Price available on application - please contact email@example.com. Discounts could be available for significant workloads.
Dr Ted Davies
T 020 3299 9000 Ext 8752
1. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection.
Autoimmunity. 2004 May; 37(3): 217-22. Vitozzi S, Lapierre P, Djilali-Saiah I, Marceau G, Beland K, Alvarez F.
- Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in paediatric patients with autoimmune hepatitis.
Autoimmunity. 2002 Dec; 35(8): 485-92. Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F.